Insider Buying Spree Continues at Cocrystal Pharma
The latest filing shows that on August 3, 2026, the group headed by Dr. Phillip Frost—operating through the Frost Gamma Investments Trust—purchased 75 000 shares of Cocrystal Pharma at a weighted average price of $0.94 per share. The acquisition brings his total holdings to 1,983,551 shares, a 10 % increase over his March 24, 2026 position. The purchase comes just weeks after the company closed a convertible‑preferred share financing that injected fresh capital into its working‑capital pool, suggesting that insider confidence is aligning with external financing efforts.
What Does the Buy Signal for Investors?
The timing and scale of the transaction are noteworthy. With the stock hovering near $1.00—a 17 % weekly gain and a 38 % YTD decline—Frost’s additional stake signals a bullish stance in a stock that has been volatile but recently rebounded from a 52‑week low of $0.76. Analysts will watch the price movement over the next trading session to see if the buy pressure translates into a breakout above the $1.02 current price. The company’s recent funding round and the positive social‑media sentiment (+10) coupled with high buzz (11 % communication intensity) hint at growing investor interest, although the market cap remains modest at $13.5 million.
Frost’s Historical Buying Pattern
Dr. Frost has been an active buyer throughout 2025 and 2026, accumulating roughly 1.4 million shares over the past 12 months. His purchases have ranged from modest 20 000‑share trades at $0.97 to a large 359 713‑share block at $1.39 in October 2025. He has also acquired warrants and stock options, indicating a long‑term commitment to the company’s upside. His most recent transaction at $0.94 represents a price point well below the 52‑week high of $2.67, implying that he is buying on a relatively discounted basis.
Implications for Cocrystal’s Future
The insider activity, coupled with the capital infusion, may signal that management is positioning the company for a series of product or partnership milestones. The firm’s focus on antiviral therapeutics for hepatitis, influenza, and norovirus could benefit from additional working capital, accelerating clinical development and potential regulatory filings. For investors, Frost’s continued buying may be interpreted as a vote of confidence, especially given the company’s historically aggressive equity transactions.
Bottom Line for Market Participants
While the stock remains volatile, the convergence of insider buying, fresh capital, and a modest uptick in social‑media buzz provides a cautiously optimistic outlook. Traders should monitor price action around the $1.02 threshold and keep an eye on any forthcoming earnings or product updates that could validate Frost’s bullish stance.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-08-03 | FROST PHILLIP MD ET AL () | Buy | 75,000.00 | 0.94 | Common Stock |
| N/A | FROST PHILLIP MD ET AL () | Holding | 27,100.00 | N/A | Common Stock |
